ADIM
SUPN icon

Alpha DNA Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Alpha DNA Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,218
Closed -$442K – 158
2024
Q4 		$442K Buy
+12,218
New +$430K 0.17% 137
2024
Q1 		– Sell
-16,248
Closed -$470K – 247
2023
Q4 		$470K Buy
+16,248
New +$431K 0.18% 139
2021
Q2 		– Sell
-87
Closed -$2K – 578
2021
Q1 		$2K Buy
+87
New +$2.43K ﹤0.01% 586

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Alpha DNA Investment Management's SUPN Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 12,218 shares — an estimated $442K sold.

Alpha DNA Investment Management first reported a position in SUPN in Q1 2021 and held it in 3 quarters. The position peaked at $470K in Q4 2023. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Alpha DNA Investment Management reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Alpha DNA Investment Management sold 12,218 Supernus Pharmaceuticals shares in Q1 2025, an estimated $442K.
  • Alpha DNA Investment Management first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Alpha DNA Investment Management's Supernus Pharmaceuticals position peaked at $470K in Q4 2023.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.